VALIANT: Pegcetacoplan for C3G or primary (idiopathic) IC-MPGN

• ESPN •
• 17 October, 2025 •
• •

Pegcetacoplan halts disease progression and reduces proteinuria in paediatric patients with C3G and primary ​ IC-MPGN: Phase 3 VALIANT study results

Christoph Licht, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Nayoa Fujita, Larry A Greenbaum, Antonio Mastrangelo, Nabil Melhem, Nicole CAJ Van de Kar, Marina Vivarelli, Dean Wallace, Virginia Taliadouros, Johan Szamosi, Katie Gordon, Zhongshen Wang, Carla M Nester

• ESPN •
• 16 October, 2025 •
• •

Pegcetacoplan for paediatric patients with​ C3 glomerulopathy or primary immune-complex mediated membranoproliferative glomerulonephritis: 52-week results from Phase 3, VALIANT Study

Nicole CAJ Van de Kar, Gema Ariceta, Yael Borovitz, Bradley P Dixon, Larry A Greenbaum, Christoph Licht, Antonio Mastrangelo, Nabil Melhem, Nayoa Fujita, Dean Wallace, Marina Vivarelli, Zhongshen Wang, Dima Decker, Johan Szamosi, Lucía Quintana-Gallardo, Carla M Nester

• IPTA •
• 18 September, 2025 •
• •

Pegcetacoplan for post-transplant patients with complement 3 glomerulopathy or primary (idiopathic) immune-complex membranoproliferative glomerulonephritis: an analysis of the phase 2 NOBLE and phase 3 VALIANT trials

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials

• WTC •
• 2 August, 2025 •
• •

Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis

Andrew S Bomback, David Kavanagh, Daniel Zecher, Julien Zuber, Ondrej Vicklicky, Li Li, Luis López Lázaro, Fadi Fakhouri

Available materials